Case Report: Lasting complete response to pembrolizumab in mismatch repair-deficient cardiac sarcoma: a genomic characterization
Sarcomas are traditionally considered “cold” tumors with poor response to immunotherapy. However, evidence accumulating over the last years shows that immune checkpoint inhibitors (ICIs) may have a role in selected sarcoma patients according to predictive markers. Here, we report the case of a woman...
Saved in:
| Main Authors: | Daniela A. Ferraro, Bettina Bisig, David C. Rotzinger, Fresia Pareja, Edoardo Missiaglia, Ioannis Voutsadakis, Krisztian Homicsko, Antonia Digklia |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1485386/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CDX2-Suppressed Colorectal Cancers Possess Potentially Targetable Alterations in Receptor Tyrosine Kinases and Other Colorectal-Cancer-Associated Pathways
by: Ioannis A. Voutsadakis
Published: (2024-10-01) -
Durable Clinical Benefit after Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer
by: Yat-Fung Chow, et al.
Published: (2023-10-01) -
Interview with the World Class Authorities Frontiers of Cancer Research: An exclusive interview with Professor Luis Diaz
by: Haruna Takeda, et al.
Published: (2025-05-01) -
Binding of RHOA G17V to p300 enhances its HAT activity: a new mechanism of epigenetic deregulation in TFH lymphoma
by: David Vallois, et al.
Published: (2025-06-01) -
Sustained disease control with pembrolizumab-lenvatinib in a patient with heavily pre-treated recurrent endometrial carcinoma: a case report
by: Alessia Lancianese, et al.
Published: (2025-06-01)